Search 

• APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs around 25 people and is led by a management team with strong background in drug development, especially in cancer immune therapy.
• Apeiron has a portfolio of innovative projects, five of which are in clinical development. Its lead project APN311 is in an ongoing phase III trial in neuroblastoma, with more than half of the patients already recruited.

RECARDIO is an Austrian based life science company founded in 2011. It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. After establishing proof-of-principle in vivo, it is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.  

Xiber is a biopharmaceutical start–up company. Xiber develops new peptide drugs to improve outcome of critical care & transplant patients. Xiber’s peptide drugs preserve organ function & prevent organ failure. Xiber will enter market by two niche indications: Acute Lung Injury & Primary Graft Dysfunction after Lung Transplantation – with a total market volume of 630 Mio. USD.
In 2015 Xiber will complete the preclinical development for both indications. A phase I clinical trial will start in the beginning of 2016.
Xiber is a spin-off of the Medical University of Vienna. The majority of the shares is owned by the founders. The University holds a non-controlling interest and rewards its shares by providing cooperation, infrastructure, facility services and management support.
To drive its developmental program till the completion of a phase I trial Xiber needs ~ 4 Mio €. This is largely covered by Austrian funds and loans. For the remaining  Xiber seeks 2 Mio € equity from VC partner. Xiber has already signed a LOI with an established VC company.